<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424370</url>
  </required_header>
  <id_info>
    <org_study_id>NI11069</org_study_id>
    <nct_id>NCT02424370</nct_id>
  </id_info>
  <brief_title>Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation</brief_title>
  <acronym>EVA-G-TAVI</acronym>
  <official_title>Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation. Multicenter Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcutaneous trans-aortic valve replacement (TAVR) is now a common procedure to treat
      symptomatic aortic stenosis. Although as effective and safe as surgical aortic valve
      replacement, it is still restricted to high surgical risk patient who are frail. The aim of
      the TAVI-EVA is to identify geriatric biomarkers that may help to predict survival and
      functional recovery after TAVR
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: identify geriatric biomarkers associated with vital/functional status
      after TAVR.

      Primary outcome measure is altered functional status at six month follow-up defined as an
      absolute decrease of 15 points of the Barthel Index.

      Secondary outcome measures are: Barthel index and survival at 6, 9 and 12 months follow-up.
      QOL during follow-up
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maintaining or improving the level of functional independence, defined as a score of Barthel index at 6 months</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score of Barthel</measure>
    <time_frame>at 6, 9 and 12 months</time_frame>
    <description>Maintaining of the same Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintain or improve the quality of life score at 6 months, defined as a score of SF-12 scale at 6 months</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate at 6 months, 9 months, 12 months</measure>
    <time_frame>at 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time after TAVI during the study</measure>
    <time_frame>up to 30 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVR</intervention_name>
    <description>Percutaneous aortic valve replacement</description>
    <other_name>Trans-aortic Valve Replacement</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        person aged over 75 years with indication for implantation of TAVI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥75

          -  Symptomatic aortic stenosis

          -  Prior geriatric evaluation

          -  Patient who agreed to answer the telephone follow-up to 6, 9 and 12 months

          -  Patient given his non-opposition to using his data

          -  Patient affiliated to the French social security.

        Exclusion criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joël BELMIN, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Philippe COLLET, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joël BELMIN, MD,PhD</last_name>
    <phone>+33(0) 1 49 59 45 65</phone>
    <email>j.belmin@cfx.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Philippe COLLET, MD,PhD</last_name>
    <phone>+33(0) 1 42 16 29 62</phone>
    <email>jean-philippe.collet@psl.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cardiologie-GH Pitié Salpétirère</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe COLLET, MD, PhD</last_name>
      <phone>+33(0) 1 42 16 29 62</phone>
      <email>jean-philippe.collet@psl.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic stenosis</keyword>
  <keyword>TAVR</keyword>
  <keyword>Frailty</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

